NFE2L2 and myeloid sarcoma: This enhanced DMF exposure in the plasma might be expected to contribute to the therapeutic effect because DMF is a potent inducer of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) pathway believed to underlie the therapeutic effect of DMF in the treatment of MS [25].